The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification
- PMID: 33367746
- DOI: 10.1093/ndt/gfaa290
The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification
Abstract
Background: In chronic kidney disease, serum phosphorus (P) elevations stimulate parathyroid hormone (PTH) production, causing severe alterations in the bone-vasculature axis. PTH is the main regulator of the receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system, which is essential for bone maintenance and also plays an important role in vascular smooth muscle cell (VSMC) calcification. The discovery of a new RANKL receptor, leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4), which is important for osteoblast differentiation but with an unknown role in vascular calcification (VC), led us to examine the contribution of LGR4 in high P/high PTH-driven VC.
Methods: In vivo studies were conducted in subtotally nephrectomized rats fed a normal or high P diet, with and without parathyroidectomy (PTX). PTX rats were supplemented with PTH(1-34) to achieve physiological serum PTH levels. In vitro studies were performed in rat aortic VSMCs cultured in control medium, calcifying medium (CM) or CM plus 10-7 versus 10-9 M PTH.
Results: Rats fed a high P diet had a significantly increased aortic calcium (Ca) content. Similarly, Ca deposition was higher in VSMCs exposed to CM. Both conditions were associated with increased RANKL and LGR4 and decreased OPG aorta expression and were exacerbated by high PTH. Silencing of LGR4 or parathyroid hormone receptor 1 (PTH1R) attenuated the high PTH-driven increases in Ca deposition. Furthermore, PTH1R silencing and pharmacological inhibition of protein kinase A (PKA), but not protein kinase C, prevented the increases in RANKL and LGR4 and decreased OPG. Treatment with PKA agonist corroborated that LGR4 regulation is a PTH/PKA-driven process.
Conclusions: High PTH increases LGR4 and RANKL and decreases OPG expression in the aorta, thereby favouring VC. The hormone's direct pro-calcifying actions involve PTH1R binding and PKA activation.
Keywords: PTH and vascular calcification; high phosphorus; leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4); receptor activator of NFκB (RANK)/RANK ligand (RANKL/OPG) system.
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Similar articles
-
RANKL, but Not R-Spondins, Is Involved in Vascular Smooth Muscle Cell Calcification through LGR4 Interaction.Int J Mol Sci. 2024 May 24;25(11):5735. doi: 10.3390/ijms25115735. Int J Mol Sci. 2024. PMID: 38891922 Free PMC article.
-
RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.Circ Res. 2009 May 8;104(9):1041-8. doi: 10.1161/CIRCRESAHA.108.189001. Epub 2009 Mar 26. Circ Res. 2009. PMID: 19325147
-
Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.J Bone Miner Res. 2002 Sep;17(9):1667-79. doi: 10.1359/jbmr.2002.17.9.1667. J Bone Miner Res. 2002. PMID: 12211438
-
Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders.Calcif Tissue Int. 2021 Apr;108(4):439-451. doi: 10.1007/s00223-020-00803-2. Epub 2021 Feb 13. Calcif Tissue Int. 2021. PMID: 33586001 Review.
-
RANK-RANKL signalling in cancer.Biosci Rep. 2016 Aug 5;36(4):e00366. doi: 10.1042/BSR20160150. Print 2016 Aug. Biosci Rep. 2016. PMID: 27279652 Free PMC article. Review.
Cited by
-
Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment.Nutrients. 2023 Mar 18;15(6):1470. doi: 10.3390/nu15061470. Nutrients. 2023. PMID: 36986200 Free PMC article.
-
Vascular Calcification in Chronic Kidney Disease: An Update and Perspective.Aging Dis. 2022 Jun 1;13(3):673-697. doi: 10.14336/AD.2021.1024. eCollection 2022 Jun. Aging Dis. 2022. PMID: 35656113 Free PMC article.
-
Emerging Roles for LGR4 in Organ Development, Energy Metabolism and Carcinogenesis.Front Genet. 2022 Jan 24;12:728827. doi: 10.3389/fgene.2021.728827. eCollection 2021. Front Genet. 2022. PMID: 35140734 Free PMC article. Review.
-
Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?Nutrients. 2021 Oct 27;13(11):3835. doi: 10.3390/nu13113835. Nutrients. 2021. PMID: 34836090 Free PMC article. Review.
-
MiR-137-mediated negative relationship between LGR4 and RANKL modulated osteogenic differentiation of human adipose-derived mesenchymal stem cells.Genet Mol Biol. 2022 Sep 19;45(3):e20210322. doi: 10.1590/1678-4685-GMB-2021-0332. eCollection 2022. Genet Mol Biol. 2022. PMID: 36121915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources